Figure 3. Four categories of BsAbs (bispecific antibodies) used in cancer therapy, based on their mechanism and target selection. (A) BsAbs that bind immune effector cells to tumor cells, including pan T-cells, γδ T-cells, NK cells (natural killer cells), etc. (B) BsAbs that bridge receptors on the same or different cells. (C) BsAbs that bind cytokines and receptors. (D) BsAbs that bridge two cytokines, respectively [50] (CC BY-SA 4.0).